Mar 31, 2022

Alkermes Q1 2022 Earnings Report

Alkermes reported strong financial results driven by LYBALVI®, ARISTADA®, and VIVITROL® sales and reiterated financial expectations for 2022.

Key Takeaways

Alkermes plc reported first quarter 2022 financial results, with total revenues of $278.5 million compared to $251.4 million for the same period in the prior year. The company reported a GAAP loss per share of $0.22 and non-GAAP earnings per share of $0.12. They reiterated their financial expectations for 2022.

Total revenues for the quarter were $278.5 million, compared to $251.4 million for the same period in the prior year.

Net sales of proprietary products for the quarter were $171.3 million, compared to $130.0 million for the same period in the prior year.

GAAP net loss was $35.9 million for the quarter, or a basic and diluted GAAP loss per share of $0.22.

Non-GAAP net income was $19.6 million for the quarter, or a non-GAAP basic and diluted earnings per share of $0.12.

Total Revenue
$279M
Previous year: $251M
+10.8%
EPS
$0.12
Previous year: $0.11
+9.1%
Gross Profit
$127M
Cash and Equivalents
$759M
Previous year: $627M
+20.9%
Free Cash Flow
$13.9M
Total Assets
$1.98B
Previous year: $1.88B
+5.3%

Alkermes

Alkermes

Alkermes Revenue by Segment

Forward Guidance

Alkermes reiterates its financial expectations for 2022, and the assumptions underlying such expectations, as set forth in its press release dated Feb. 16, 2022.

Revenue & Expenses

Visualization of income flow from segment revenue to net income